Lower rates of bladder cancer recurrence and progression
demonstrated in clinics with a high level of blue light cystoscopy
(BLC®) use in primary patients
Photocure sponsor of the Residents Day during the NUF
congress
OSLO,
Norway, June 13, 2022 /PRNewswire/ -- Photocure
ASA (OSE: PHO) announces that positive data from a Danish
population registry study featuring nearly 10,000 bladder cancer
patients was presented at the Nordisk Urologisk Forening (NUF)
congress in Helsinki, Finland last
week. NUF was being held June 8-11,
2022 as an in-person event for the first time since 2019.
Photocure's presence at and commitment to NUF was reinforced by
sponsoring the Residents Day event for this year's congress. Nordic
Residents in Urology is a NUF group, which aims to increase
collaboration and networking between young urologists in the Nordic
countries in order to improve overall education and research
opportunities.
Nordisk Urologisk Forening is an association of the national
urological societies in Denmark,
Norway, Sweden, Finland and Iceland, supporting close cooperation of
Nordic urologists in various fields of education, science and
clinical work. The NUF meeting is bi-annual, bringing together
Nordic urologists, nurses and healthcare industry to meet and share
best practice. Photocure, The Bladder Cancer Company, was present
in Helsinki during the whole
event.
In the scientific program on Bladder Cancer topics, BLC was
prominently featured again this year: a Danish population study
assessing recurrence and progression impact of BLC using national
registries in Denmark was
presented at NUF.
The study abstract entitled "Use of photodynamic diagnosis (PDD)
at primary TURB*: Potential influence on recurrence and progression
rates in NMIBC in a registry-based study using a country cohort"
shows beneficial impact on recurrence and progression in patients
treated at clinics who have a higher level of use of BLC in primary
patients. The results are based on data from nearly 10,000 patients
identified through the Danish National Patient Registry,
corresponding to all newly diagnosed NMIBC patients in Denmark in the period 2011-2017.
Linea Blichert-Refsgaard (MD, PhD student) presented this study
live on June 9 and in a poster,
concluding that "Common use of PDD in the primary TURB at
department level seems to be associated with lower 5-year
recurrence and progression risks."
Jørgen Bjerggaard Jensen (MD, DMSc, Professor, Consultant in
Urology, Chairman of the Danish Bladder Cancer Group and the Nordic
Urothelial Cancer Research Group, Department of Urology Aarhus
University Hospital put the importance of these study results into
perspective, stating: "These real world data results show the
true potential of adding better visual diagnostic methods in
endoscopy compared to the old standard with conventional white
light."
The abstract is available here: http://www.nuf2021.fi/abstracts/
and will be published in 'Scandinavian Journal of Urology' after the congress.
* TURB / TURBT: Transurethral resection of bladder tumor
** NMIBC: Non-muscle invasive bladder cancer
Note to editors:
All trademarks mentioned in this release are protected by law
and are registered trademarks of Photocure ASA.
About Bladder Cancer
Bladder cancer ranks as the 8th most common cancer
worldwide – the 5th most common in men – with
1 720 000 prevalent cases (5-year prevalence
rate)1a, 573 000 new cases and more than
200 000 deaths in 2020.1b
Approx. 75% of all bladder cancer cases occur in
men.1 It has a high recurrence rate with up to 61% in
year one and up to 78% over five years.2 Bladder cancer
has the highest lifetime treatment costs per patient of all
cancers.3
Bladder cancer is a costly, potentially progressive disease for
which patients have to undergo multiple cystoscopies due to the
high risk of recurrence. There is an urgent need to improve both
the diagnosis and the management of bladder cancer for the benefit
of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive
bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC),
depending on the depth of invasion in the bladder wall. NMIBC
remains in the inner layer of cells lining the bladder. These
cancers are the most common (75%) of all BC cases and include the
subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the
cancer has grown into deeper layers of the bladder wall. These
cancers, including subtypes T2, T3 and T4, are more likely to
spread and are harder to treat.4
1 Globocan. a) 5-year prevalence / b)
incidence/mortality by population. Available at:
https://gco.iarc.fr/today, accessed [January
2022].
2 Babjuk M, et al. Eur Urol. 2019; 76(5):
639-657
3 Sievert KD et al. World J Urol
2009;27:295–300
4 Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html
About
Hexvix®/Cysview® (hexaminolevulinate
HCl)
Hexvix/Cysview is a drug that preferentially accumulates in
cancer cells in the bladder, making them glow bright pink during
Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview,
compared to standard white light cystoscopy alone, improves the
detection of tumors and leads to more complete resection, fewer
residual tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all
other markets. Photocure is commercializing Cysview/Hexvix directly
in the U.S. and Europe and has
strategic partnerships for the commercialization of Hexvix/Cysview
in China, Chile, Australia, and New
Zealand. Please refer to
https://photocure.com/partners/our-partners for further information
on our commercial partners.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative
solutions to improve the lives of bladder cancer patients. Our
unique technology, making cancer cells glow bright pink, has led to
better health outcomes for patients worldwide. Photocure is
headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information,
please visit us at www.photocure.com, www.hexvix.com,
www.cysview.com
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/photocure/r/positive-data-from-the-danish-national-patient-registry-presented-at-the-2022-nordic-urologisk-foren,c3583623
The following files are available for download:
|
https://mb.cision.com/Main/17498/3583623/1591349.pdf
|
Release
|